Last reviewed · How we verify
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml is a Local anesthetic + opioid combination Small molecule drug developed by Dr Madeleine Wilwerth. It is currently in Phase 3 development for Regional anesthesia and analgesia for epidural administration, Postoperative pain management via epidural infusion. Also known as: ambulatory group.
Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.
Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief. Used for Regional anesthesia and analgesia for epidural administration, Postoperative pain management via epidural infusion.
At a glance
| Generic name | Levobupivacaine 0.07% + Sufentanil 0.3µg/ml |
|---|---|
| Also known as | ambulatory group |
| Sponsor | Dr Madeleine Wilwerth |
| Drug class | Local anesthetic + opioid combination |
| Target | Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Pain Management |
| Phase | Phase 3 |
Mechanism of action
Levobupivacaine is a long-acting local anesthetic that inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory/motor blockade in a localized region. Sufentanil is a potent synthetic opioid agonist at mu opioid receptors that enhances analgesia and reduces pain perception. This combination is used for epidural or regional anesthesia to provide both sensory blockade and opioid-mediated analgesia.
Approved indications
- Regional anesthesia and analgesia for epidural administration
- Postoperative pain management via epidural infusion
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Pruritus
- Urinary retention
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levobupivacaine 0.07% + Sufentanil 0.3µg/ml CI brief — competitive landscape report
- Levobupivacaine 0.07% + Sufentanil 0.3µg/ml updates RSS · CI watch RSS
- Dr Madeleine Wilwerth portfolio CI
Frequently asked questions about Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
What is Levobupivacaine 0.07% + Sufentanil 0.3µg/ml?
How does Levobupivacaine 0.07% + Sufentanil 0.3µg/ml work?
What is Levobupivacaine 0.07% + Sufentanil 0.3µg/ml used for?
Who makes Levobupivacaine 0.07% + Sufentanil 0.3µg/ml?
Is Levobupivacaine 0.07% + Sufentanil 0.3µg/ml also known as anything else?
What drug class is Levobupivacaine 0.07% + Sufentanil 0.3µg/ml in?
What development phase is Levobupivacaine 0.07% + Sufentanil 0.3µg/ml in?
What are the side effects of Levobupivacaine 0.07% + Sufentanil 0.3µg/ml?
What does Levobupivacaine 0.07% + Sufentanil 0.3µg/ml target?
Related
- Drug class: All Local anesthetic + opioid combination drugs
- Target: All drugs targeting Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)
- Manufacturer: Dr Madeleine Wilwerth — full pipeline
- Therapeutic area: All drugs in Anesthesia and Pain Management
- Indication: Drugs for Regional anesthesia and analgesia for epidural administration
- Indication: Drugs for Postoperative pain management via epidural infusion
- Also known as: ambulatory group
- Compare: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml vs similar drugs
- Pricing: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml cost, discount & access